Published today on $TGTX, the three piece of great news for the company in the past few weeks, and how my model has a target price of $289 five years from now.
@Biohazard3737 I have said roughly the same. But this is a far left position. It's universal healthcare with good drug pricing to industry. And it would work! Welcome, comrade! ๐
https://t.co/dnZ6wcwDT4
My biggest mistake in modern election analysis is thinking people want moderate choices in politics. The pendulum shift is going to be huge. With an upcoming blue wave, I think every biotech investment will have to be *actual* innovation or radically increase patient access somehow. (Biosims maybe, finally?) I never had a position but $APGE for $11 billion will look insane after the 2028 election IMHO. All these big pharmas will clean up over the next two years but they should probably start spending their dry powder more wisely. Single payer option is coming eventually and government payers are going to have a lot of power in the 2030s is my guess. Hybrid U.S./E.U. style market
My biggest mistake in modern election analysis is thinking people want moderate choices in politics. The pendulum shift is going to be huge. With an upcoming blue wave, I think every biotech investment will have to be *actual* innovation or radically increase patient access somehow. (Biosims maybe, finally?) I never had a position but $APGE for $11 billion will look insane after the 2028 election IMHO. All these big pharmas will clean up over the next two years but they should probably start spending their dry powder more wisely. Single payer option is coming eventually and government payers are going to have a lot of power in the 2030s is my guess. Hybrid U.S./E.U. style market
Random biotech things that could do still do well in a very blue environment off the top of my head: Biosims, gene therapy, things that help underserved populations (Hep Delta - $VIR ?), oncology drugs with survival benefit and large addressable population (will work in any environment), drugs proven to reduce hospitalization (system too fragmented to pay up-front right now), drugs that treat high prevalence conditions that affect younger people (dermatology, GI, auto-immune conditions)...
My biggest mistake in modern election analysis is thinking people want moderate choices in politics. The pendulum shift is going to be huge. With an upcoming blue wave, I think every biotech investment will have to be *actual* innovation or radically increase patient access somehow. (Biosims maybe, finally?) I never had a position but $APGE for $11 billion will look insane after the 2028 election IMHO. All these big pharmas will clean up over the next two years but they should probably start spending their dry powder more wisely. Single payer option is coming eventually and government payers are going to have a lot of power in the 2030s is my guess. Hybrid U.S./E.U. style market
$TGTX as much as I like the AZER data & also how nothing was priced in - the MOVE in $TGTX today I am confident in has all to do with $NVS underwhelming data - as that was one of last bear thesis even BofA had https://t.co/J45ywtLoYv
@mtheory11bio I meant more on the readout in 2H 2027. Sadly a lot of these Phase 2 signals in developmental disabilities have disappeared in larger trials. But yep very tough environment for clinical stage single asset companies for sure.
TRES A CERO!!! ๐บ๐ธ๐บ๐ธ๐บ๐ธ
What a win for Mauricio Pochettinoโs USMNT against Mexico โ with goals coming from 18-year-old Julian Hall, a GOLAZO from 17-year-old Cavan Sullivan for his first USMNT goal, and Malik Tillman to make it 3-0.
A STATEMENT win from the USMNT ๐ฅ
@EyeFarma I'm helping grow your reach so we can share these beautiful thoughts with the world. Don't listen to the haters concerned about guidance. We know what's important
When will @Snapchat adopt the same app usage limitations @Meta just agreed to implement (albeit through a settlement)? Parental control is good, but insufficient. It creates massive friction between parents and children -- needlessly -- if the companies limit access for minors.